Under the agreement, the companies will advance development of IBI3009, Innovent’s ADC candidate, which has received IND approvals in the US, China, and Australia.

AbbVie's latest acquisition target is Nimble Therapeutics, which will give AbbVie a lead asset, an oral peptide for treating psoriasis.

It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.

Optimizing Drug Packaging: Strategic Approaches for De-Risking Drug Development ...